Bruce A Mueller

List of Publications by Year
in descending order

112 papers	4,345 citations	117571 34 h-index	123376 61 g-index
117 all docs	117 docs citations	117 times ranked	3192 citing authors

#	Article	IF	Citations
1	Therapeutic monitoring of vancomycin for serious methicillin-resistantStaphylococcus aureusinfections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy, 2020, 77, 835-864.	0.5	640
2	Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clinical Infectious Diseases, 2020, 71, 1361-1364.	2.9	142
3	Drug-Associated Renal Dysfunction. Critical Care Clinics, 2006, 22, 357-374.	1.0	119
4	Quantifying the Effect of Changes in the Hemodialysis Prescription on Effective Solute Removal with a Mathematical Model. Journal of the American Society of Nephrology: JASN, 1999, 10, 601-609.	3.0	119
5	Impact of the Nutritional Regimen on Protein Catabolism and Nitrogen Balance in Patients With Acute Renal Failure. Journal of Parenteral and Enteral Nutrition, 1996, 20, 56-62.	1.3	103
6	Vancomycin pharmacokinetics in acute renal failure: Preservation of nonrenal clearance. Clinical Pharmacology and Therapeutics, 1991, 50, 688-694.	2.3	90
7	Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Critical Care Medicine, 2011, 39, 19-25.	0.4	89
8	Antibiotic dosing in critically ill patients with acute kidney injury. Nature Reviews Nephrology, 2011, 7, 226-235.	4.1	85
9	Renal Dosing of Antibiotics: Are We Jumping the Gun?. Clinical Infectious Diseases, 2019, 68, 1596-1602.	2.9	85
10	Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury. Critical Care, 2008, 12, 235.	2.5	83
11	Continuous Venovenous Hemofiltration: An Alternative to Continuous Arteriovenous Hemofiltration and Hemodiafiltration in Acute Renal Failure. American Journal of Kidney Diseases, 1991, 18, 451-458.	2.1	82
12	Daptomycin Clearance during Modeled Continuous Renal Replacement Therapy. Blood Purification, 2006, 24, 548-554.	0.9	78
13	Comparison of Imipenem Pharmacokinetics in Patients With Acute or Chronic Renal Failure Treated With Continuous Hemofiltration. American Journal of Kidney Diseases, 1993, 21, 172-179.	2.1	74
14	Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. American Journal of Kidney Diseases, 2003, 42, 1253-1259.	2.1	73
15	Higher Renal Replacement Therapy Dose Delivery Influences on Drug Therapy. Artificial Organs, 2003, 27, 808-814.	1.0	70
16	How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?. Diagnostic Microbiology and Infectious Disease, 2015, 82, 92-103.	0.8	68
17	Amino Acid Requirements in Critically Ill Patients with Acute Kidney Injury Treated with Continuous Renal Replacement Therapy. Pharmacotherapy, 2008, 28, 600-613.	1.2	65
18	Influence of Hemodialysis on Gentamicin Pharmacokinetics, Removal During Hemodialysis, and Recommended Dosing. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 355-361.	2.2	58

#	Article	IF	Citations
19	Antibiotic Dosing in Patients With Acute Kidney Injury. Journal of Intensive Care Medicine, 2016, 31, 164-176.	1.3	56
20	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillinâ€Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Healthâ€System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy, 2020, 40, 363-367.	1.2	56
21	Pre dialysis of blood prime in continuous hemodialysis normalizes pH and electrolytes. Pediatric Nephrology, 2003, 18, 1177-1183.	0.9	54
22	THE CLINICAL APPLICATION OF CRRTâ€"CURRENT STATUS: Drug Dosing During Continuous Renal Replacement Therapy. Seminars in Dialysis, 2009, 22, 185-188.	0.7	54
23	Mucositis management practices for hospitalized patients: National survey results. Journal of Pain and Symptom Management, 1995, 10, 510-520.	0.6	49
24	Enhanced clearance of highly protein-bound drugs by albumin-supplemented dialysate during modeled continuous hemodialysis. Nephrology Dialysis Transplantation, 2008, 24, 231-238.	0.4	47
25	Antibiotic Dosing in Critically Ill Patients Receiving <scp>CRRT</scp>: Underdosing is Overprevalent. Seminars in Dialysis, 2014, 27, 441-445.	0.7	47
26	Principles and Operational Parameters to Optimize Poison Removal with Extracorporeal Treatments. Seminars in Dialysis, 2014, 27, 371-380.	0.7	46
27	Trace element removal during in vitro and in vivo continuous haemodialysis. Nephrology Dialysis Transplantation, 2007, 22, 2970-2977.	0.4	45
28	Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2010, 25, 1279-1284.	0.4	44
29	Effects of Peridialytic Oral Supplements on Nutritional Status and Quality of Life in Chronic Hemodialysis Patients. , 2009, 19, 145-152.		43
30	Intradialytic Administration of Daptomycin in End Stage Renal Disease Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1190-1194.	2.2	40
31	Quantification of creatinine kinetic parameters in patients with acute renal failure. Kidney International, 1998, 54, 554-560.	2.6	39
32	Urea Kinetics During Continuous Hemofiltration. ASAIO Journal, 1992, 38, M664-M667.	0.9	37
33	Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Critically <scp>Ill</scp> Patients Receiving Continuous Venovenous Hemodialysis and/or Extracorporeal Membrane Oxygenation. Pharmacotherapy, 2012, 32, 1061-1069.	1.2	37
34	In vitro clearance of trace elements via continuous renal replacement therapy. , 2004, 14, 214-219.		36
35	Medication Dosing in Critically Ill Patients With Acute Kidney Injury Treated With Renal Replacement Therapy. American Journal of Kidney Diseases, 2013, 61, 490-500.	2.1	35
36	Dialyzer-dependent changes in solute and water permeability with bleach reprocessing. American Journal of Kidney Diseases, 1999, 33, 87-96.	2.1	34

#	Article	IF	Citations
37	We Underdose Antibiotics in Patients on <scp>CRRT</scp>. Seminars in Dialysis, 2016, 29, 278-280.	0.7	34
38	Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy. Journal of Clinical Pharmacology, 2016, 56, 1277-1287.	1.0	33
39	Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 555-561.	1.2	33
40	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 281-284.	0.6	33
41	Falsely elevated serum vancomycin concentrations in hemodialysis patients. American Journal of Kidney Diseases, 1996, 27, 67-74.	2.1	32
42	Pharmacokinetics of Ertapenem in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis or Hemodiafiltration. Antimicrobial Agents and Chemotherapy, 2014, 58, 1320-1326.	1.4	32
43	Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. American Journal of Kidney Diseases, 2001, 37, 766-776.	2.1	31
44	Transplacental Passage of Vancomycin in Noninfected Term Pregnant Women. Obstetrics and Gynecology, 2007, 109, 1105-1110.	1.2	30
45	Antibiotic Pharmacokinetic and Pharmacodynamic Considerations in Patients With Kidney Disease. Advances in Chronic Kidney Disease, 2010, 17, 392-403.	0.6	30
46	Uremic pruritus. American Journal of Health-System Pharmacy, 1996, 53, 2159-2170.	0.5	28
47	EFFICACY OF CONVECTIVE REMOVAL OF PLASMA MEDIATORS OF ENDOTOXIC SHOCK BY CONTINUOUS VENO-VENOUS HEMOFILTRATION. Shock, 1996, 5, 149-154.	1.0	28
48	Linezolid Clearance During Continuous Venovenous Hemodiafiltration: A Case Report. Pharmacotherapy, 2003, 23, 1071-1075.	1.2	28
49	Continuous venovenous hemodiafiltration trace element clearance in pediatric patients: a case series. Pediatric Nephrology, 2009, 24, 807-813.	0.9	27
50	Subcutaneous Terbutaline Use in CKD to Reduce Potassium Concentrations. American Journal of Kidney Diseases, 2005, 45, 1040-1045.	2.1	26
51	Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy. Blood Purification, 2017, 44, 16-23.	0.9	25
52	Carbamazepine and the active epoxide metabolite are effectively cleared by hemodialysis followed by continuous venovenous hemodialysis in an acute overdose. Hemodialysis International, 2011, 15, 412-415.	0.4	24
53	Antibiotic Dosing in Continuous Renal Replacement Therapy. Advances in Chronic Kidney Disease, 2017, 24, 219-227.	0.6	24
54	Modeled Dalbavancin Transmembrane Clearance during Intermittent and Continuous Renal Replacement Therapies. Blood Purification, 2010, 30, 37-43.	0.9	23

#	Article	IF	Citations
55	Longitudinal Hemodiafilter Performance in Modeled Continuous Renal Replacement Therapy. Blood Purification, 2011, 32, 82-88.	0.9	23
56	Selection of narcotic analgesics for pain associated with pancreatitis. American Journal of Health-System Pharmacy, 1998, 55, 480-486.	0.5	21
57	Drug Dosing Considerations in Alternative Hemodialysis. Advances in Chronic Kidney Disease, 2007, 14, e17-e26.	0.6	21
58	Daptomycin Pharmacokinetics and Pharmacodynamics in a Pooled Sample of Patients Receiving Thrice-Weekly Hemodialysis. Antimicrobial Agents and Chemotherapy, 2013, 57, 864-872.	1.4	21
59	A Monte Carlo Simulation Approach for Betaâ€Lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy. Journal of Clinical Pharmacology, 2018, 58, 1254-1265.	1.0	20
60	Small and Middle Molecular Weight Solute Clearance in Nocturnal Intermittent Peritoneal Dialysis. Peritoneal Dialysis International, 1999, 19, 534-539.	1.1	19
61	Effect of Gender on the Pharmacokinetics of Ofloxacin. Pharmacotherapy, 1999, 19, 442-446.	1.2	19
62	Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. American Journal of Kidney Diseases, 2003, 42, 342-349.	2.1	19
63	Tedizolid Adsorption and Transmembrane Clearance during in vitro Continuous Renal Replacement Therapy. Blood Purification, 2015, 40, 66-71.	0.9	19
64	Telavancin and Hydroxy Propyl-Î²-Cyclodextrin Clearance during Continuous Renal Replacement Therapy: An in vitro Study. International Journal of Artificial Organs, 2009, 32, 745-751.	0.7	17
65	In Vitro Glucose Kinetics during Continuous Renal Replacement Therapy: Implications for Caloric Balance in Critically Ill Patients. International Journal of Artificial Organs, 2013, 36, 861-868.	0.7	17
66	Prevention of hypophosphatemia during continuous renal replacement therapyâ€"An overlooked problem. Seminars in Dialysis, 2018, 31, 213-218.	0.7	17
67	Adding to the Armamentarium. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 373-375.	2.2	16
68	Survey of pharmacistsâ€™ antibiotic dosing recommendations for sustained low-efficiency dialysis. International Journal of Clinical Pharmacy, 2016, 38, 127-134.	1.0	16
69	Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation. SAGE Open Medicine, 2018, 6, 205031211877325.	0.7	16
70	Antibiotic Exposure Profiles in Trials Comparing Intensity of Continuous Renal Replacement Therapy. Critical Care Medicine, 2019, 47, e863-e871.	0.4	16
71	Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach. Clinical Nephrology, 2016, 86, 43-50.	0.4	16
72	Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy. Blood Purification, 2018, 46, 214-219.	0.9	15

#	Article	IF	Citations
73	CAHP-210 dialyzer influence on intra-dialytic vancomycin removal. Nephrology Dialysis Transplantation, 2002, 17, 1649-1654.	0.4	13
74	Safety of Daptomycin in Patients Receiving Hemodialysis. Pharmacotherapy, 2011, 31, 665-672.	1.2	13
75	The Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in a Critically Ill Pediatric Patient Receiving Extracorporeal Membrane Oxygenation and Continuous Venovenous Hemodialysis. Journal of Pediatric Pharmacology and Therapeutics, 2012, 17, 173-176.	0.3	13
76	The Effects of Peracetic Acid-Hydrogen Peroxide Reprocessing on Dialyzer Solute and Water Permeability. Pharmacotherapy, 1999, 19, 1042-1049.	1.2	11
77	In vitro clearance of trace elements via continuous renal replacement therapy. , 2004, 14, 214-219.		11
78	In silico trials using Monte Carlo simulation to evaluate ciprofloxacin and levofloxacin dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. Renal Replacement Therapy, 2016, 2, .	0.3	11
79	Pharmacokinetics of Intravenously Administered Levofloxacin in Men and Women. Pharmacotherapy, 2005, 25, 1310-1318.	1.2	10
80	Intradialytic Oral Nutritional Supplements Improve Quality of Life. American Journal of Kidney Diseases, 2013, 61, 349.	2.1	10
81	Dose Timing of Aminoglycosides in Hemodialysis Patients: A Pharmacology View. Seminars in Dialysis, 2016, 29, 204-213.	0.7	10
82	In vitro clearance of trace elements via continuous renal replacement therapy. Journal of Renal Nutrition, 2004, 14, 214-9.	0.1	10
83	Selected Pharmacokinetic Issues in Patients with Chronic Kidney Disease. Blood Purification, 2007, 25, 133-138.	0.9	9
84	Evaluation and Development of Vancomycin Dosing Schemes to Meet New AUC/MIC Targets in Intermittent Hemodialysis Using Monte Carlo Simulation Techniques. Journal of Clinical Pharmacology, 2021, 61, 211-223.	1.0	9
85	Lowâ€Molecular Weight Protein Removal by Highâ€Flux Dialyzers: Basic Mechanisms and Effect ofâ€ƒReprocessing. Seminars in Dialysis, 1999, 12, 349-354.	0.7	8
86	Therapeutic Controversies: Optimizing Anemia Management in Hospitalized Patients with End-Stage Renal Disease. Annals of Pharmacotherapy, 2009, 43, 276-282.	0.9	8
87	Reenvisioning Assessment for the Academy and the Accreditation Council for Pharmacy Education's Standards Revision Process. American Journal of Pharmaceutical Education, 2013, 77, 141.	0.7	7
88	Pharmacist leads primary care team to improve diabetes care. American Journal of Health-System Pharmacy, 2009, 66, 622-624.	0.5	6
89	Antimicrobial Doses in Continuous Renal Replacement Therapy: A Comparison of Dosing Strategies. Critical Care Research and Practice, 2016, 2016, 1-6.	0.4	6
90	Effect of cisapride on QT interval in patients with end-stage renal disease. American Journal of Cardiology, 2000, 86, 873-875.	0.7	5

#	Article	IF	Citations
91	Ethambutol Optic Neuropathy in a Hemodialysis Patient Receiving a Guideline-Recommended Dose. Journal of Neuro-Ophthalmology, 2013, 33, 421-423.	0.4	5
92	Influence of hemodialysis on regadenoson clearance in an in vitro hemodialysis model. Journal of Nuclear Cardiology, 2018, 25, 234-239.	1.4	5
93	Preparation times and costs for various solutions used for continuous renal replacement therapy. American Journal of Health-System Pharmacy, 2018, 75, 808-815.	0.5	5
94	Harmonizing antibiotic regimens with renal replacement therapy. Expert Review of Anti-Infective Therapy, 2020, 18, 887-895.	2.0	5
95	Erythema Multiforme Secondary to Amoxicillin/Clavulanic Acid Exposure. Annals of Pharmacotherapy, 1999, 33, 109-110.	0.9	3
96	Acetaminophen clearance during ex vivo continuous renal replacement therapies. Journal of Artificial Organs, 2018, 21, 215-219.	0.4	3
97	Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis. Renal Failure, 2019, 41, 118-125.	0.8	3
98	Size Matters: The Influence of Patient Size on Antibiotics Exposure Profiles in Critically Ill Patients on Continuous Renal Replacement Therapy. Antibiotics, 2021, 10, 1390.	1.5	3
99	Outcomes of an Erythropoietic Growth Factor Interchange Program in Hospitalized Chronic Hemodialysis Patients. Hospital Pharmacy, 2007, 42, 119-125.	0.4	2
100	Etanercept Clearance during an in vitro Model of Continuous Venovenous Hemofiltration. Blood Purification, 2009, 28, 348-353.	0.9	2
101	Daptomycin pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Critical Care Medicine, 2011, 39, 1244-1245.	0.4	2
102	Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy. Antibiotics, 2021, 10, 1184.	1.5	2
103	Ofloxacin clearance during continuous hemofiltration. American Journal of Kidney Diseases, 2003, 42, 1326-1327.	2.1	1
104	Vibration Enhances Clearance of Solutes With Varying Molecular Weights During In Vitro Hemodialysis. ASAIO Journal, 2013, 59, 140-144.	0.9	1
105	Contemporary Vancomycin Dosing in Chronic Hemodialysis (HD) Patients Does Not Meet AUC Targets: Development of a New Dosing Model Using Monte Carlo Simulation (MCS). Open Forum Infectious Diseases, 2016, 3, .	0.4	1
106	Impact of hemodialysis on the concentrations of sodium and potassium during infusion of sodium thiosulfate using an In Vitro hemodialysis model. PLoS ONE, 2019, 14, e0224767.	1.1	1
107	Questions on Vancomycin Dosing. Clinical Infectious Diseases, 2020, 73, e1777-e1778.	2.9	1
108	Ceftolozane/Tazobactam Clearance During In Vitro Continuous Renal Replacement Therapy (CRRT). Open Forum Infectious Diseases, 2016, 3, .	0.4	0

#	Article	IF	Citations
109	â€œIn Through the Out Doorâ€• Pediatric Critical Care Medicine, 2016, 17, 373-374.	0.2	0
110	Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis. Journal of Antimicrobial Chemotherapy, 2021, 77, 174-180.	1.3	0
111	Drug Dosing in Patients with Acute Kidney Injury and in Patients Undergoing Renal Replacement Therapy. , 2009, , 1727-1730.		0
112	Drug Dosing in Acute Kidney Injury and During Renal Replacement Therapy. , 2010, , 241-251.		0